Advanced Imaging to Predict Progressive Lung Fibrosis in ILD
Official title: Advanced Imaging for Pulmonary Fibrosis
Funded at Massachusetts General Hospital · NIH-11380706 · Data updated 2026-11-12
This grant tests imaging tools to identify people with non-IPF interstitial lung disease who will develop progressive fibrotic lung disease, so doctors can tailor treatment early.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $588,218 |
| NIH project number | 5R01HL171240-03 |
| Project ID | NIH-11380706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with non-IPF interstitial lung disease who are at risk of developing progressive pulmonary fibrosis and are evaluated for disease management.
✕Less likely to help
If your condition does not progress or if imaging results are inconclusive, you may not derive direct benefit.
What this research studies
If you have a non-IPF interstitial lung condition, this project uses two cutting-edge imaging methods together to predict who will progress to worse lung fibrosis. The goal is to spot high-risk patients early so they can start antifibrotic therapy sooner and plan care more effectively. The researchers will use an imaging probe that targets fibrotic changes and combine it with other advanced imaging measurements to improve prediction accuracy. This work aims to better guide clinical decisions, referrals, and enrollment in future trials. Participation would involve imaging procedures and clinical follow-up aligned with standard care.
Why it matters
Potential benefit: Potentially earlier and more accurate identification of people at risk for worsening fibrosis, enabling timely treatment and better planning.
How similar studies have gone: Previous results like the INBUILD trial support antifibrotic therapy in progression, but using dual advanced imaging to predict progression is a novel approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Montesi, Sydney — Massachusetts General Hospital
- Study coordinator: Montesi, Sydney
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.